Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Announcement PICI Network Investigators to Unveil Cancer Research Breakthroughs at AACR 2024 Announcement, From Bench to Fireside Episode Eight: Robbie Majzner, MD Announcement, From Bench to Fireside Episode Seven: Evanna Mills, PhD Announcement, From Bench to Fireside Episode Six: Justin Eyquem, PhD Announcement, From Bench to Fireside Episode Five: Nina Bhardwaj, MD, PhD Announcement, From Bench to Fireside Episode Four: Christopher A. Klebanoff, MD